The best way to purchase FUB-AMB

The best way to get legal high with us to buy FUB-AMB for sale

AMB-FUBINACA (also known as FUB-AMB and MMB-FUBINACA) is an indazole-based synthetic cannabinoid that is a potent agonist for the cannabinoid receptors, with Ki values of 10.04 nM at CB1 and 0.786 nM at CB2 and EC50 values of 0.5433 nM at CB1 and 0.1278 nM at CB2, and has been sold online as a designer drug. It was originally developed by Pfizer, describing the compound in a patent in 2009, but it was later abandoned and never tested on humans.

AMB-FUBINACA (also known as FUB-AMB) is a synthetic cannabinoid used as an active ingredient in synthetic cannabis products. Pfizer first developed it in 2009, but it was never tested on humans and subsequently abandoned. In the following years, it has frequently been reported as a suspected cause of recreational drug overdoses due to its potent activity and availability. In 2017 and the first half of 2018 alone, it accounted for the majority of positive drug test results for synthetic marijuana products. The DEA briefly considered adding AMB-FUBINACA to the list of Schedule I drugs but ultimately rejected its proposal, citing a lack of evidence.

AMB-FUBINACA, also known as FUB-AMB and MMB-FUBINACA, was originally developed by Pfizer. It is a potent cannabinoid agonist and has been reported to be abused in the United States by drug usersAMB-FUBINACA (also known as FUB-AMB and MMB-FUBINACA) is a synthetic cannabinoid that was initially developed by Pfizer, which described the compound in a patent in 2009. AMB-FUBINACA was later abandoned and never tested on humans. However, it has been sold online as an illicit designer drug under names such as "SPANK," "Mad Scientist," "Cloud 9," "Matrix," and "Crazy Clown."

Looking for online research chemicals FUB-AMB vendor USA

AMB-FUBINACA is an indazole-based synthetic cannabinoid potent agonist for cannabinoid receptors. It has Ki values of 10.04 nM at CB1 and 0.786 nM at CB2, and EC50 values of 0.5433 nM at CB1 and 0.1278 nM at CB2 and has been sold online as a designer drug.

Pfizer originally developed the indazole-3-carbothioamide (IAC) series of synthetic cannabinoids in 2009; they were never tested on humans and were abandoned by them. AMB-FUBINACA is one of the most commonly identified psychoactive substances in drug seizures in the United States, with a potency trend higher than other analogs such as UR-144 or 5F-ABP.

IAC stands for indazole-3-carbothioamide. It is a synthetic cannabinoid with a chemical formula of C23H25N3O. IAC was first developed by Pfizer in 2009 and abandoned in favor of other synthetic compounds with higher potency. IAC has been detected in drug seizures across the US, but its popularity has waned since its initial production.

AMB-FUBINACA ((N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) is a potent synthetic cannabinoid receptor agonist. It was first described in the late 2000s by forensic scientists at the National Institute for Public Health and the Environment, investigating numerous smoking blends sold as "herbal incense."